<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14096">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00333970</url>
  </required_header>
  <id_info>
    <org_study_id>F3460-V</org_study_id>
    <secondary_id>JMF0001</secondary_id>
    <nct_id>NCT00333970</nct_id>
  </id_info>
  <brief_title>Predictors of Response to Cognitive Remediation in Schizophrenia</brief_title>
  <official_title>Predictors of Response to Cognitive Remediation in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which variables predict improvement on a cognitive
      training task battery, used for patients with schizophrenia, and to determine the proportion
      of patients whose performance returns to normal following cognitive training
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been suggested that level of cognitive function is a &quot;rate-limiter&quot; for the efficacy
      of other psychosocial treatments in schizophrenia. Cognitive remediation, which entails
      training and practice of successively more difficult cognitive exercises, has shown efficacy
      in improving cognitive function. However, the rate of improvement has not been uniform among
      patients receiving this intervention. Given the time- and cost-intensiveness of cognitive
      remediation, it is important to examine variables that will predict response to this
      treatment, as well as to examine the clinical significance of any improvement.

      The current proposal has two aims: 1) to determine which neuropsychological, demographic,
      and illness variables predict response to cognitive remediation training; and 2) to
      determine the proportion of patients whose performance returns to normal following cognitive
      remediation training. For the first part of the proposed study, 50 outpatients diagnosed
      with schizophrenia spectrum disorders will be invited to participate in an 8-week trial of
      cognitive remediation training. Detailed neuropsychological, demographic, symptom and
      illness course variables will be collected prior to training, at the conclusion of training,
      and 4 months from study intake. In order to answer the second question, additional data on
      the computerized task performance for healthy controls will be collected, and compared to
      patient data, in order to determine what constitutes normal-range performance
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cognitive Performance</measure>
    <time_frame>baseline and 2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in verbal memory scores from baseline to end of active phase (2 months), measured as trials 1-5 total score on the California Verbal Learning Test -II (range 0-80, higher scores represent better performance).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>cognitive remediation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cognitive remediation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment as usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>treatment as usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>cognitive remediation</intervention_name>
    <description>individual cognitive training</description>
    <arm_group_label>cognitive remediation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia spectrum disorder

          -  English speakers

          -  Clinically stable

          -  No substance abuse in past 30 days

        Exclusion Criteria:

          -  Traumatic brain injury

          -  Neurological disease

          -  Diagnosis of mental retardation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna Fiszdon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Connecticut Health Care System (West Haven)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Health Care System (West Haven)</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 6, 2014</lastchanged_date>
  <firstreceived_date>June 2, 2006</firstreceived_date>
  <firstreceived_results_date>October 2, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cognition</keyword>
  <keyword>neuropsychology</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>treatment efficacy</keyword>
  <keyword>cognitive remediation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>103 participants were enrolled. Of those, 75 were found eligible, completed baseline assessments and were then randomized to either Arm 1 (n=50) or Arm 2 (n=25). The remaining 28 participants were either discontinued from the study by the PI or chose to withdraw prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>cognitive remediation
cognitive remediation: individual cognitive training</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>treatment as usual</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>individuals randomized to Arm 1 or Arm 2</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>cognitive remediation
cognitive remediation: individual cognitive training</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>treatment as usual</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="75"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="75"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="56"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Performance</title>
        <description>Change in verbal memory scores from baseline to end of active phase (2 months), measured as trials 1-5 total score on the California Verbal Learning Test -II (range 0-80, higher scores represent better performance).</description>
        <time_frame>baseline and 2 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>individuals who were randomized and completed 2 month assessments</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>cognitive remediation
cognitive remediation: individual cognitive training</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>treatment as usual</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cognitive Performance</title>
            <description>Change in verbal memory scores from baseline to end of active phase (2 months), measured as trials 1-5 total score on the California Verbal Learning Test -II (range 0-80, higher scores represent better performance).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4.97" spread="1.38"/>
                  <measurement group_id="O2" value="-2.30" spread="1.98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>cognitive remediation
cognitive remediation: individual cognitive training</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>treatment as usual</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pulled chest muscle</sub_title>
                <description>presented to ER with chest pain diagnosed as pulled chest muscle; determined not to be study related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>worsening of psychiatric symptoms</sub_title>
                <description>all determined not to be study related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>substance abuse</sub_title>
                <description>determined not to be study related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <description>determined not to be study related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>shortness of breath</sub_title>
                <description>participant reported to ER complaining of shortness of breath; determined not to be study related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <description>determined not to be study related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>toe pain</sub_title>
                <description>determined not to be study related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>worsening of psychiatric symptoms</sub_title>
                <description>determined not to be study related</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>substance use</sub_title>
                <description>determined not to be study related</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joanna Fiszdon</name_or_title>
      <organization>VA Connecticut Healthcare System</organization>
      <phone>203-932-5711 ext 2231</phone>
      <email>joanna.fiszdon@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
